A Low-Molecular-Weight Antagonist for the Human Thyrotropin Receptor with Therapeutic Potential for Hyperthyroidism
Endocrinology Neumann et al. 149: 5945 Supplemental Data
Supplemental Data
Files in this Data Supplement:
- Supplementary Figure 1 - Binding of 125I-bTSH to HEK-EM 293 cells stably expressing the TSHR. Cells were subjected to displacement studies using 180.000-200.000 cpm 125I-bTSH and increasing concentrations of bTSH or compound 52. Compound 52 does not displace 125I-bTSH. The data are presented as mean ± SEM of two independent experiments, each performed in duplicate.
- Supplementary Figure 2 - Compound 52 (c52) inhibits thyroperoxidase (TPO) gene expression in primary cultures of human thyrocytes from two donors. Thyrocytes were incubated for 24 h with bTSH at its EC50 concentration (1.8 nM) with or without the indicated concentrations of compound 52. Cells receiving compound 52 were pre-incubated for 1 h with compound 52 at the same concentration used during the 24 h treatment. The data are presented as mean ± SEM of two independent experiments, each performed in duplicate.
- Supplemental Information - Materials and Methods, and references